Cinnarizine 25mg – 56 tablets
Selective blocker of slow calcium channels, reduces the flow of calcium ions into the cells and reduces their content in the depot of plasmolemma, reduces the tone of smooth, muscle arterioles, enhances the vasodilating effect of carbon dioxide. Directly affecting the smooth muscles of blood vessels, reduces their reaction to nutrients (adrenaline, noradrenaline, dopamine, angiotensin, vasopressin).
It has a vasodilating effect (especially in relation to the vessels of the brain), without having a significant effect on blood PRESSURE. Shows moderate antihistamine activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system. It is effective both at the initial and chronic insufficiency of cerebral circulation (including in patients in the residual stage of ischemic stroke). In patients with peripheral circulation disorders improves blood supply to organs and tissues (including myocardium). Increases elasticity of erythrocyte membranes, their ability to deformation, reduces blood viscosity. Increases muscle resistance to hypoxia.
The drug is resorbed in the stomach and intestines. Cmax in plasma is reached after ingestion 1-3 hours Connection Cinnarizine to plasma proteins is 91%. Completely metabolized in liver (via dezalkilirovania). T1/2 is 4 hours Excreted as metabolites: 1/3 – 2/3 of the kidneys and – with the kalovymi masses.
— ischemic stroke;
– post-stroke conditions (incl. after hemorrhagic stroke);
— a condition after cranial trauma;
– dyscirculatory encephalopathy — ;
– vestibular disorders (including Meniere’s disease; dizziness, tinnitus, nystagmus, nausea and vomiting labyrinth origin);
– prevention of kinetosis (motion sickness, sea and air sickness);
– migraine (prevention of attacks);
— senile dementia;
– peripheral circulation disorders (“intermittent” lameness, obliterating atherosclerosis, obliterating thrombangiitis (Buerger’s disease), Raynaud’s disease, diabetic angiopathy, thrombophlebitis, trophic disorders (including trophic and varicose ulcers, pre-gangrenous conditions).
Inside, preferably after a meal. In case of circulatory disorders of the brain-25-50 mg (1-2 tab.) 3 times/ day; in violation of peripheral circulation-50-75 mg (2-3 tab.) 3 times/day; with vestibular disorders – 25 mg 3 times / day; with kinetosis (“road” disease): adults – 25 mg for half an hour before the road (if necessary, repeated intake of 25 mg after 6 hours). The dose for children is 1/2 the dosage recommended for adults.
With high sensitivity to the drug treatment begins with 1/2 dose, increasing it gradually. The course of treatment from a few weeks to several months.
At the beginning of treatment should refrain from potentially dangerous activities that require increased concentration and psychomotor reactions, as well as alcohol.
Due to the presence of antihistamine effect, Cinnarizine may affect the result of anti-doping control of athletes (false positive), as well as Cinnarizine can neutralize positive reactions during skin diagnostic tests (4 days before the study treatment should be canceled).
With long – term use, it is recommended to conduct a control examination of liver function, kidney, peripheral blood picture.
Patients suffering from Parkinson’s disease should be prescribed only in cases where the benefits of its appointment exceed the possible risk of deterioration.